Enhanced Genomics
Enhanced Genomics operates a digital platform focused on decoding the causal biology behind genetic variations to accelerate drug discovery. The company uses its proprietary GenLink 3D multi-omics platform to analyze genome folding and link disease-associated variants to target genes across the entire human genome, enabling faster identification of high-confidence therapeutic targets for common diseases including…
Funding snapshot
About
Enhanced Genomics operates a digital platform focused on decoding the causal biology behind genetic variations to accelerate drug discovery. The company uses its proprietary GenLink 3D multi-omics platform to analyze genome folding and link disease-associated variants to target genes across the entire human genome, enabling faster identification of high-confidence therapeutic targets for common diseases including autoimmune conditions. Founded in 2020 and headquartered in Cambridge, United Kingdom, Enhanced Genomics has raised approximately $19M in Series A funding from investors including BGF, Parkwalk, and Meltwind Advisory. The company leverages advances in 3D genomics and chromatin conformation capture to understand how non-coding genetic variants affect gene expression through long-range DNA interactions, addressing the challenge that most disease-associated genetic variants identified by genome-wide association studies fall outside protein-coding regions and their target genes remain unknown.
Business model
Genomics > Enabling Technologies > Technology Platforms > Genome Structure and Function
Founders & team highlights
Serial Founder
Team background
College Wise > University of Pennsylvania
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.